News & Events
January 17, 2019
Critical Path Institute Celebrates Expanded Operations with Opening of European HeadquartersC-Path in the EU will work to accelerate the development of new therapies through innovative methodologies for endorsement by regulators of pharmaceutical products TUCSON, Ariz., January 17, 2019 — Critical Path Institute (C-Path) is excited to announce the launch of Critical Path Institute, Ltd. (C-Path, Ltd.) in Ireland, a fully-owned subsidiary that will enable C-Path to...
January 8, 2019
Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial ResistanceTUCSON, Ariz., January 8, 2019 — Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and Microbiome Division of the Translational Genomics Research Institute (TGen) — have received a Phase 1 Concept Validation grant from the Flinn Foundation, of $400,000 over 12 months, to develop and pilot a framework enabling the state...
December 18, 2018
Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker InitiativeBiomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 — Critical Path Institute (C-Path) announced today that its Type 1 Diabetes (T1D) Consortium has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the FDA’s decision to accept the...
December 12, 2018
U.S. Food and Drug Administration Awards Contract to Critical Path Institute for Kidney Transplant DatabasePatient-level data will inform the creation of drug development tools and speed development of new immunosuppressive treatments TUCSON, Ariz., December 12, 2018 — The U.S. Food and Drug Administration (FDA) has awarded a contract to Critical Path Institute (C-Path) in support of a new project to create a database of patient-level clinical trial data that...
November 5, 2018
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s DiseaseCritical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy development for AD and related forms of dementia TUCSON, Ariz., November 5, 2018 — The Critical Path Institute (C-Path) is pleased to announce that its Critical Path for Alzheimer’s Disease (CPAD) consortium has refined and refocused its mission in celebration of...